3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
16
Carcinoma, Renal Cell
12
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Carcinoma, Transitional Cell
4
Neoplasms
3
Lung Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoma, Hepatocellular
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Basal Cell
2
Carcinoma
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Ipilimumab
×
30 days
×
Clear all
No trials found.